- Home
- EYPT vs LXEO Comparison
EYPT vs LXEO Comparison
Compare EYPT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | LXEO |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.9M | 396.5M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | EYPT | LXEO |
|---|---|---|
| Price | $4.62 | $4.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $31.80 | $18.44 |
| AVG Volume (30 Days) | ★ 6.3M | 818.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,115.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $3.99 |
| 52 Week High | $19.11 | $10.99 |
Technical Indicators
Market Signals| Indicator | EYPT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 47.30 |
| Support Level | $3.95 | $4.39 |
| Resistance Level | $15.17 | $5.38 |
| Average True Range (ATR) | 0.51 | 0.26 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 26.30 | 18.56 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.